Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

Bullboard (TSXV:SBM)

View:
Prev ... 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 ... Next
Comment by noclue80on Jan 19, 2023 4:41am

RE:RE:RE:RE:SkinMedica® Launches Even & Correct

I don't think they would change the active ingredient when moving to XXX 2.0 I would expect a new product (line, best case :))
75
Discussion
Comment by Transperanceon Jan 19, 2023 1:03am

RE:RE:RE:RE:Q&A

This is not how you value a company, it can only be done by hard figures, provided by the company. 
76
Discussion
Comment by lscfaon Jan 18, 2023 1:05pm

RE:RE:RE:SkinMedica® Launches Even & Correct

1067 may be added to an existing product in next iteration. e.g. Even & Correct 2.0.....They had Lytera, then Lytera 2.0.  https://www.skinmedica.com/us/product-category/brighteners/95772 ...more  
125
Discussion
Comment by biorunon Jan 18, 2023 12:43pm

RE:RE:RE:Q&A

I for one would like to hear Bieber's professional opinion on the inherent value of the existing IP portfolio as well how he sees the advantages of carbohydrate chemistry that Geraldine is ...more  
129
Discussion
Comment by Transperanceon Jan 18, 2023 12:08pm

RE:RE:Q&A

I think you can expect a Q&A with Geraldine and Howard in the near future. 
66
Discussion
Comment by Engcan77on Jan 18, 2023 11:24am

RE:RE:RE:Q&A

It was nice to see a good turn out for the Q&A. I thought there was good questions asked. Thanks to those who stepped up and asked them. The webinar could have been set up for a bit longer this ...more  
101
Discussion
Comment by forhandlarenon Jan 18, 2023 11:04am

RE:RE:SkinMedica® Launches Even & Correct

I hope this product will beccome popular since that will be favourable for us when replaced by TFC-1067.
79
Discussion
Comment by biorunon Jan 18, 2023 11:02am

RE:AbbVie Inc. 41st Annual J.P. Morgan HC meetg

Ok, realize some have questions about how much money we will make etc But just stand back for a moment and reflect on the fact that Sirona science was chosen amongst an entire world of possibilities. ...more  
112
Discussion
Comment by lscfaon Jan 18, 2023 9:51am

RE:SkinMedica® Launches Even & Correct

As Skinmedica's dark spot cream does NOT contain 1067 investors are once again clueless as to how Allergan plans to use 1067 making it impossible to value.
68
Discussion
Post by noclue80on Jan 18, 2023 5:15am

AbbVie Inc. 41st Annual J.P. Morgan HC meetg

Rick Gonzalez - Chairman and Chief Executive Officer Moving to Slide 13. We're the clear leader in aesthetics, a $14 billion global market, which is largely cash pay. Our portfolio is anchored ...more  
334
Discussion
Comment by forhandlarenon Jan 18, 2023 4:27am

RE:RE:Q&A

Geraldine will bring enthusism into the room, one hour of her time will not kill the company.
80
Discussion
Comment by biofoolon Jan 18, 2023 4:26am

RE:RE:Jan 17/23 Q & A session

Oh biorun. Is that you talking to yourself?   
74
Discussion
Comment by Turtle4on Jan 18, 2023 4:17am

RE:Q&A

Please let Geraldine do her work in the lab and don't force her to join the Q&A Sessions. Bieber already mentioned that she should focus on the science and not on public relations!
93
Discussion
Post by forhandlarenon Jan 18, 2023 2:50am

Q&A

I think the Q&A was a positive experience for the shareholders as well as the management and we agreed to continue with the meetings on a quarterly cadence. This Q&A focused on the business ...more  
419
Discussion
Prev ... 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities